Is Metropolis Healthcare (METROPOLIS) overvalued or fairly valued?

MarketChacha shows Metropolis Healthcare's valuation in context — a forward P/E of about 37.5, a price-to-book of about 7.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Metropolis Healthcare's revenue?

Metropolis Healthcare reported revenue of ₹1,646 Cr for FY2026, with net profit of ₹190 Cr, per official filings.

What is the share price of Metropolis Healthcare (METROPOLIS)?

Metropolis Healthcare last traded at ₹570.10 (-0.6% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Metropolis Healthcare

METROPOLIS · NSE · Healthcare · India

₹570.10-0.6%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 10:00 AM

Snapshot

TickerMETROPOLIS

ExchangeNSE

SectorHealthcare

IndustryDiagnostics & Research

CountryIndia

CEOMr. Surendran Chemmenkotil

HeadquartersMumbai, India

Market cap₹11,822 Cr

P/B7.8

Volume1.18L

Websitewww.metropolisindia.com

Filings tracked0

About Metropolis Healthcare

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters48.9%
Institutions44.9%
Public & other6.2%

58 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend12.4% → 11.5%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 13% · PAT 10%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹489 Cr · EPS 3.40

Est. earnings growth +34.3%

Next fiscal year

Rev ₹2,160 Cr · EPS 15.19

Est. earnings growth +24.2%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹412.2552-wk range₹600.00

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹11,822 Cr

Day change

-0.6%

Fwd P/E

37.5

P/B

7.8

Div yield

0.35%

Beta

0.22

Revenue (FY2026)

₹1,646 Cr

Net margin

11.5%

Revenue CAGR (3y)

+12.8%

Profit CAGR (3y)

+10.0%

Net profit (FY2026)

₹190 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about METROPOLIS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹1,646 Cr	₹190 Cr	11.5%
FY2025	₹1,331 Cr	₹145 Cr	10.9%
FY2024	₹1,208 Cr	₹128 Cr	10.6%
FY2023	₹1,148 Cr	₹143 Cr	12.4%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹425 Cr	₹51 Cr	12.0%
2025Q4	₹406 Cr	₹41 Cr	10.2%
2025Q3	₹429 Cr	₹53 Cr	12.3%
2025Q2	₹386 Cr	₹45 Cr	11.7%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.